Skip to main content
. Author manuscript; available in PMC: 2017 Dec 12.
Published in final edited form as: Oncogene. 2017 Jun 12;36(42):5793–5807. doi: 10.1038/onc.2017.142

Table 2. Anti-EMP2 IgG1 inhibits secondary tumor formation.

The take rates of secondary tumors created from HEC1A tumors treated previously with control or anti-EMP2 IgG1 were tabulated. The extreme limiting dilution analysis (ELDA) was used to compare the frequency of cancer stem cells between the control and anti-EMP2 IgG1 treated animals48.

Treatment
# Cells Injected Ctrl IgG EMP2 IgG1
50,000 6/6 6/6
5000 6/6 5/6
500 6/6 0/6
CSC Frequency*
(95% CI)		 1:1
(1–535)		 1:3528
(1421–8758)
*

p=1.2×10−5; chi-square=19.2